The Association of hsCRP and Radiotherapy-Induced Toxicity in Patients With Nasopharyngeal Carcinoma
Study Details
Study Description
Brief Summary
The primary purpose of this study is to explore the association of high sensitivity C-reactive protein (hsCRP) and radiotherapy(RT)-induced toxicity in patients with nasopharyngeal carcinoma. In each patient, hsCRP levels in the pre- and post-RT plasma samples will be measured according to the schedule we set.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Group 1: Patients with neoadjuvant chemotherapy The patients of group1 will receive one of the following treatments: neoadjuvant chemotherapy & concurrent chemoradiotherapy neoadjuvant chemotherapy & radiotherapy neoadjuvant chemotherapy & radiotherapy & adjuvant chemotherapy |
Other: clinical measurements
Only clinical parameters were recorded, no intervention was made.
|
| Group 2: Patients without neoadjuvant chemotherapy The patients of group2 will receive one of the following treatments: concurrent chemoradiotherapy concurrent chemoradiotherapy & adjuvant chemoradiotherapy radiotherapy & adjuvant chemotherapy |
Other: clinical measurements
Only clinical parameters were recorded, no intervention was made.
|
Outcome Measures
Primary Outcome Measures
- hsCRP levels [Through treatments completion，12 weeks]
The hscrp levels in the plasma samples from each participant were measured at the following time points: at the time of diagnosis completion/before the initiation of the first neoadjuvant chemotherapy before the initiation of each neoadjuvant chemotherapy before the initiation of the first radiotherapy during radiotherapy, once a week 1 week and 4weeks after the last radiotherapy
- Incidence of adverse events [Through treatments completion，12 weeks]
All adverse events were recorded during treatment(for example, oral mucositis, dermatitis).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients were pathologically newly diagnosed with nasopharyngeal carcinoma and had no previous history of other tumors
-
According to the treatment strategies of doctors, patients need to receive radiotherapy with or without chemotherapy (for example, neoadjuvant chemotherapy, concurrent chemotherapy, adjuvant chemotherapy) or targeted therapy
-
Willingness to sign the informed consent and return to enrolling institution for follow-up and data collection
Exclusion Criteria:
-
Patients do not conform to the inclusion criteria
-
Pregnant or Nursing women
-
Men or women of childbearing potential who are unwilling to employ adequate contraception
-
Vital organs dysfunction(for example, kidneys, heart, liver, lungs, brain)
-
Other contraindications or unsuitable conditions for radiotherapy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Jiarong Chen, MD
Investigators
- Principal Investigator: Jiarong Chen, PhD, Affiliated Jiangmen Hospital of Sun Yat-Sen University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JM0019002